<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-164510</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study</dc:title>
<dc:description xml:lang="en">Background and objectives: Ixekizumab demonstrated greater efficacy than placebo and etanercept in UNCOVER-3. Subgroup analysis of Latin American patients was performed. We report 12-week and 60-week data. Patients and methods: Analysis included 102 Latin American patients randomized to receive placebo (n = 14), etanercept 50 mg twice weekly (n=30), or ixekizumab 160-mg starting dose followed by 80 mg every 2 weeks (Q2W; n = 29) or every 4 weeks (Q4W; n = 29). At week 12, patients maintaining efficacy response and adequate overall safety were assigned, at the discretion of the investigator, to long-term extension with ixekizumab Q4W. Results: At week 12, Psoriasis Area and Severity Index (PASI) 100 scores were 0%, 20.0% (p = 0.075 vs placebo), 62.1% (p &lt; 0.001 vs placebo; p = 0.001 vs etanercept), and 48.3% (p = 0.002 vs placebo; p = 0.023 vs etanercept) for placebo, etanercept, ixekizumab Q2W, and ixekizumab Q4W, respectively. Among patients who continued therapy up to week 60 (n = 97), PASI 100 scores were 71.4%, 60.0%, 77.8%, and 57.7% for patients who received induction placebo, etanercept, ixekizumab Q2W, and ixekizumab Q4W, respectively (non-responder imputation). By week 60, &amp;#8805;1 serious adverse event was experienced by 7.1% (n = 1/14), 3.3% (n = 1/30), 14.8% (n = 4/27), and 0% (n = 0/26) of patients who received induction placebo, etanercept, ixekizumab Q2W, and ixekizumab Q4W, respectively. There were no cases of active tuberculosis with ixekizumab treatment through 60 weeks. Conclusions: In Latin American patients, both ixekizumab dosing regimens demonstrated greater efficacy than etanercept for treating psoriasis over 12 weeks. The safety profile of ixekizumab through 60 weeks was well tolerated and consistent with the overall profile (AU)</dc:description>
<dc:creator>Galimberti, L</dc:creator>
<dc:creator>Cruz Fernandez, C de la</dc:creator>
<dc:creator>Romiti, R</dc:creator>
<dc:creator>McKean-Matthews, M</dc:creator>
<dc:creator>Gürbüz, S</dc:creator>
<dc:creator>Goncalves, L</dc:creator>
<dc:creator>Valenzuela, F</dc:creator>
<dc:language>en</dc:language>
<dc:description xml:lang="es">Antecedentes y objetivos: Ixekizumab demostró una mayor eficacia que el placebo y etanercept en el estudio UNCOVER-3. Tras realizar un análisis del subgrupo de pacientes latinoamericanos, se presentan los resultados transcurridas 12 y 60 semanas. Pacientes y métodos: El análisis incluyó a 102 pacientes latinoamericanos aleatorizados para la administración de placebo (n=14), etanercept 50 mg 2 veces por semana (n = 30), o ixekizumab 160mg como dosis inicial y 80mg cada 2 semanas (Q2W; n=29) o 4 semanas (Q4W; n = 29). A la semana 12 los pacientes con buena respuesta de eficacia y ausencia de efectos adversos fueron asignados al tratamiento de ampliación a largo plazo con ixekizumab Q4W, a discreción del investigador. Resultados: A las 12 semanas las puntuaciones del PASI fueron del 0%, 20% (p = 0,075 vs placebo), 62,1% (p &lt; 0,001 vs placebo; p = 0,001 vs etanercept) y 48,3% (p = 0,002 vs placebo; p = 0,023 vs etanercept) para placebo, etanercept, ixekizumab Q2W, e ixekizumab Q4W, respectivamente. Entre los pacientes que prosiguieron la terapia hasta la semana 60 (n = 97) las puntuaciones PASI 100 fueron del 71,4%, 60%, 77,8%, y 57,7% para los pacientes a quienes se administró placebo de inducción, etanercept, ixekizumab Q2W e ixekizumab Q4W, respectivamente (imputación del no respondedor). En la semana 60 &amp;#8805;1 presentaron reacción adversa grave el 7,1% (n = 1/14), 3,3% (n = 1/30), 14,8% (n = 4/27) y 0% (n = 0/26) de los pacientes a quienes se administró placebo, etanercept, ixekizumab Q2W e ixekizumab Q4W, respectivamente. No se produjeron casos de tuberculosis activa con el tratamiento de ixekizumab a lo largo de las 60 semanas. Conclusiones: En los pacientes latinoamericanos ambos regímenes de dosificación de ixekizumab demostraron mayor eficacia que etanercept para el tratamiento de la psoriasis durante 12 semanas. En cuanto al perfil de seguridad, ixekizumab a lo largo de 60 semanas fue bien tolerado y consistente con el perfil general (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;108(6): 550-563, jul.-ago. 2017. graf, tab</dc:source>
<dc:identifier>ibc-164510</dc:identifier>
<dc:title xml:lang="es">Comparación de ixekizumab y etanercept o placebo en la psoriasis de moderada a grave: análisis del subgrupo de pacientes latinoamericanos de la fase 3 del estudio aleatorizado UNCOVER-3</dc:title>
<dc:subject>^d1716^s22074</dc:subject>
<dc:subject>^d8022^s22080</dc:subject>
<dc:subject>^d7344^s22073</dc:subject>
<dc:subject>^d29623</dc:subject>
<dc:subject>^d11350^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d55985^s22073</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201708</dc:date>
</metadata>
</record>
</ibecs-document>
